Canaccord Adams downgrades Exelixis (Nasdaq: EXEL) from Buy to Hold, while maintaining its $7.30 price target.

The firm cites ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE